Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia

被引:46
|
作者
Leoni, Veronica [1 ]
Biondi, Andrea
机构
[1] Milano Bicocca Univ, Paediat Haematol Oncol Dept, San Gerardo Hosp, Fdn MBBM, Monza, Italy
关键词
STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; ADULT PATIENTS; HYPER-CVAD; ALLOGENEIC TRANSPLANTATION; MARROW TRANSPLANTATION; COMPLETE REMISSION; REDUCED-INTENSITY; ELDERLY-PATIENTS; IMATINIB;
D O I
10.3324/haematol.2015.124016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:295 / 299
页数:6
相关论文
共 50 条
  • [21] DERMATOLOGIC ADVERSE EVENTS OF BCR-ABL TYROSINE KINASE INHIBITORS
    Shatokhina, E. A.
    Turkina, A. G.
    Kruglova, L. S.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2020, 65 (02): : 154 - 173
  • [23] Tyrosine kinase inhibitors in BCR/ABL positive ALL
    Lopez-Enriquez, A. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Bcr-Abl tyrosine kinase inhibitors- current status
    Anum Mughal
    Hafiz Muhammad Aslam
    Aga Muhammad Hammad Khan
    Shafaq Saleem
    Ribak Umah
    Maria Saleem
    Infectious Agents and Cancer, 8
  • [25] An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia
    Raponi, Sara
    De Propris, Maria Stefania
    Wai, Hobert
    Intoppa, Stefania
    Elia, Loredana
    Diverio, Daniela
    Vitale, Antonella
    Foa, Robin
    Guarini, Anna
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (12): : 1767 - 1770
  • [26] The ABL and JAK Tyrosine Kinase Pathways Are Co-Activated in BCR/ABL1 Positive Acute Lymphoblastic Leukemia
    Bhagavathi, S.
    Aviv, H.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2016, 18 (06): : 958 - 958
  • [27] Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
    H Pfeifer
    T Lange
    S Wystub
    B Wassmann
    J Maier
    A Binckebanck
    A Giagounidis
    M Stelljes
    M Schmalzing
    U Dührsen
    L Wunderle
    H Serve
    P Brück
    A Schmidt
    D Hoelzer
    O G Ottmann
    Leukemia, 2012, 26 : 1475 - 1481
  • [28] Serial Analysis of BCR-ABL Kinase Domain Mutations Prior to and During Imatinib Treatment for Newly Diagnosed and Recurrent BCR-ABL Positive Acute Lymphoblastic Leukemia.
    Pfeifer, Heike
    Wystub, Sylvia
    Wassmann, Barbara
    Maier, Jaqueline
    Lange, Thoralf
    Hochhaus, Andreas
    Hoelzer, Dieter
    Ottmann, Oliver
    BLOOD, 2009, 114 (22) : 806 - 806
  • [29] Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
    Pfeifer, H.
    Lange, T.
    Wystub, S.
    Wassmann, B.
    Maier, J.
    Binckebanck, A.
    Giagounidis, A.
    Stelljes, M.
    Schmalzing, M.
    Duehrsen, U.
    Wunderle, L.
    Serve, H.
    Brueck, P.
    Schmidt, A.
    Hoelzer, D.
    Ottmann, O. G.
    LEUKEMIA, 2012, 26 (07) : 1475 - 1481
  • [30] BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival
    Barbosa Pagnano, Katia Borgia
    Bendit, Israel
    Boquimpani, Carla
    De Souza, Carmino Antonio
    Miranda, Eliana C. M.
    Zalcberg, Ilana
    Larripa, Irene
    Nardinelli, Luciana
    Silveira, Rosana Antunes
    Fogliatto, Laura
    Spector, Nelson
    Funke, Vaneuza
    Pasquini, Ricardo
    Hungria, Vania
    Chiattone, Carlos Sergio
    Clementino, Nelma
    Conchon, Monika
    Beatriz Moiraghi, Elena
    Lopez, Jose Luis
    Pavlovsky, Carolina
    Pavlovsky, Miguel A.
    Cervera, Eduardo E.
    Antonio Meillon, Luis
    Simoes, Belinda
    Hamerschlak, Nelson
    Magarinos Bozzano, Alicia Helena
    Mayta, Ernesto
    Cortes, Jorge
    Bengio, Raquel M.
    CANCER INVESTIGATION, 2015, 33 (09) : 451 - 458